Clinical Trials
37 trialsStudy of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Chinese PLA General Hospital
Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy
Cairo University
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
SCARF-1
Karolinska Institutet
VICD
Medical College of Wisconsin
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
Brigham and Women's Hospital
TSTENT
Rabin Medical Center
TRIABETES
University of Pittsburgh
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
IREKI
Institut du Cancer de Montpellier - Val d'Aurelle
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
University of California, Los Angeles
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
CKD AGE
Centre Hospitalier Saint Joseph Saint Luc de Lyon
SELF-BREATHE RCT for Chronic Breathlessness
King's College Hospital NHS Trust
STONE
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CECIL
University of Santo Tomas Hospital, Philippines
Mesenchymal Stem Cells After Renal or Liver Transplantation
University of Liege
LVPK
BTG International Inc.
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
OPTIMAL
Oxford University Hospitals NHS Trust
OPTI-AGED
Centre Hospitalier Universitaire de Saint Etienne
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Massachusetts General Hospital
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
Renal Hypothermia During Partial Nephrectomy
Ottawa Hospital Research Institute
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
EuLITE
University Hospital Birmingham
RENVEL
PETHEMA Foundation
MAPLE
Brigham and Women's Hospital
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
BTG International Inc.
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties
Tokushukai Medical Group
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
Tokushukai Medical Group
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente